Microbix Biosystems Inc (MBXBF)

[yielddude]

Currently this market is a monopoly for TPA by Genetech. The catheter clearance market in the U.S. is estimated currently at $350M+. It will likely take 3 years to bring Kinlytic to market. Estimated fair value of Kinlytic is roughly $95M. Current market cap on Microbix is $38M. This is an FDA approved drug. They have to find a manufacturer, then show that the newly manufactured drug is similar/equivalent to the previous product. Sequel Pharma will be paying the estimated $35M for this process. Microbix/Sequel have been in discussions with the FDA about how to proceed, and based on these discussions, Sequel has made the commitment to fully find this and proceed.